Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, shared a post on LinkedIn:
“ASCO25 GU (Genitourinary) cancer highlights – pleased to write this commentary in Doximity from Advent Health, Central Florida Cancer Institute, Orlando, Florida”
More posts featuring ASCO25.